comparemela.com

Latest Breaking News On - Enanta pharmaceuticals company profile - Page 4 : comparemela.com

StockNews.com Upgrades Enanta Pharmaceuticals (NASDAQ:ENTA) to Hold

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Thursday. ENTA has been the subject of several other research reports. JPMorgan Chase & Co. lowered shares of Enanta Pharmaceuticals from a “neutral” rating to an “underweight” […]

Canada
Tennessee
United-states
Arizona
Enanta-pharmaceuticals-stock-performance
Proshare-advisors
Jpmorgan-chase-co
Enanta-pharmaceuticals-inc
Analyst-recommendations-for-enanta-pharmaceuticals
Nasdaq
Enanta-pharmaceuticals-company-profile

Enanta Pharmaceuticals, Inc. Expected to Post Q2 2024 Earnings of ($2.61) Per Share (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc. Expected to Post Q2 2024 Earnings of ($2.61) Per Share (NASDAQ:ENTA)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Canada
Profund-advisors
Enanta-pharmaceuticals
Abbott-laboratories
Mirae-asset-global-investments-co
Commonwealth-of-pennsylvania-public-school-empls-retrmt
Nasdaq
Enanta-pharmaceuticals-company-profile
Institutional-investors-weigh-in-on-enanta-pharmaceuticals
Jefferies-financial-group
News-ratings-for-enanta-pharmaceuticals-daily

Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to "Hold" at Jefferies Financial Group

Jefferies Financial Group cut shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) from a buy rating to a hold rating in a research note released on Tuesday, MarketBeat.com reports. They currently have $18.00 price target on the biotechnology company’s stock, down from their previous price target of $49.00. ENTA has been the topic of a […]

Texas
United-states
Canada
Enanta-pharmaceuticals
Enanta-pharmaceuticals-company-profile
Abbott-laboratories
Texas-permanent-school-fund-corp
Jump-financial
News-ratings-for-enanta-pharmaceuticals-daily
Enanta-pharmaceuticals-inc
Renaissance-technologies

Enanta Pharmaceuticals (NASDAQ:ENTA) Releases Q3 Earnings Guidance

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) issued an update on its third quarter earnings guidance on Monday morning. The company provided earnings per share guidance of ($1.86) for the period, compared to the consensus earnings per share estimate of ($2.25). The company issued revenue guidance of $18.9 million, compared to the consensus revenue estimate […]

Canada
Montreal
Quebec
Tennessee
United-states
Institutional-trading-of-enanta-pharmaceuticals
Enanta-pharmaceuticals-trading-down
Jpmorgan-chase-co
Royal-bank
Tennessee-treasury-department
News-ratings-for-enanta-pharmaceuticals-daily

JMP Securities Trims Enanta Pharmaceuticals (NASDAQ:ENTA) Target Price to $42.00

Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) had its price objective reduced by JMP Securities from $65.00 to $42.00 in a research report released on Tuesday morning, MarketBeat reports. JMP Securities currently has a market outperform rating on the biotechnology company’s stock. Other research analysts have also issued research reports about the company. Royal Bank of […]

Texas
United-states
Canada
Analyst-recommendations-for-enanta-pharmaceuticals
Enanta-pharmaceuticals
Hedge-funds-weigh-in-on-enanta-pharmaceuticals
Texas-permanent-school-fund-corp
Jump-financial
Enanta-pharmaceuticals-price-performance
Renaissance-technologies
Abbott-laboratories

vimarsana © 2020. All Rights Reserved.